Olaoba Olamide T, Adelusi Temitope I, Yang Ming, Maidens Tessa, Kimchi Eric T, Staveley-O'Carroll Kevin F, Li Guangfu
Department of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.
Department of Immunology, University of Connecticut Health Center, Farmington, CT 06030, USA.
Cancers (Basel). 2024 May 9;16(10):1808. doi: 10.3390/cancers16101808.
Pancreatic cancer is the sixth leading cause of cancer-related mortality globally. As the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) represents up to 95% of all pancreatic cancer cases, accounting for more than 300,000 deaths annually. Due to the lack of early diagnoses and the high refractory response to the currently available treatments, PDAC has a very poor prognosis, with a 5-year overall survival rate of less than 10%. Targeted therapy and immunotherapy are highly effective and have been used for the treatment of many types of cancer; however, they offer limited benefits in pancreatic cancer patients due to tumor-intrinsic and extrinsic factors that culminate in drug resistance. The identification of key factors responsible for PDAC growth and resistance to different treatments is highly valuable in developing new effective therapeutic strategies. In this review, we discuss some molecules which promote PDAC initiation and progression, and their potential as targets for PDAC treatment. We also evaluate the challenges associated with patient outcomes in clinical trials and implications for future research.
胰腺癌是全球癌症相关死亡的第六大主要原因。作为胰腺癌最常见的形式，胰腺导管腺癌（PDAC）占所有胰腺癌病例的95%，每年导致超过30万人死亡。由于缺乏早期诊断以及对现有治疗的高难治性反应，PDAC的预后非常差，5年总生存率低于10%。靶向治疗和免疫治疗非常有效，已被用于治疗多种类型的癌症；然而，由于导致耐药性的肿瘤内在和外在因素，它们对胰腺癌患者的益处有限。确定导致PDAC生长和对不同治疗耐药的关键因素对于开发新的有效治疗策略非常有价值。在这篇综述中，我们讨论了一些促进PDAC起始和进展的分子，以及它们作为PDAC治疗靶点的潜力。我们还评估了临床试验中与患者预后相关的挑战以及对未来研究的影响。
